anti d1 receptor antibody  (Millipore)

Journal: medRxiv

Article Title: A Translational Neuroscience & Computational Evaluation of a D1R Partial Agonist for Schizophrenia (TRANSCENDS): Rationale and Study Design of a Brain-Based Clinical Trial

doi: 10.1101/2025.04.18.25326082

Figure Lengend Snippet: TRANSCENDS Study Overview. A. Translational Framework for Spatial Working Memory (sWM) Neural Biomarkers Overview. The translational framework designed for the TRANSCENDS study is that D1R/D5R agonists improve working memory in schizophrenia by restoring deficient inhibitory tuning within cortical microcircuits. A) i) Spatial working memory task from Cho et al. . The task has 4 conditions: Motor, Spatial Working Memory (No Distractor), Distractor Near (20° or 40° distance), Distractor Far (60° or 80° distance), and provides a continuous measure of sWM precision; ii) the sWM task is optimized for probing human cognitive circuits using fMRI. Panel refers to from Cho et al showing regions activated by sWM across encoding and delay epochs, including frontoparietal circuitry; iii) sWM task is grounded in studies of primate physiology, which suggest that optimal stimulation of the D1R occurs in a dose-dependent, inverted-U manner to support sWM (adapted from Goldman-Rakic, Arnsten, and colleagues ( , , )). B. The TRANSCENDS informatics infrastructure is designed to provide automated data quality assurance, interoperable electronic data capture (EDC), validated systems integration, seamless data sharing, and an analytics platform for biomarker readout. C. Overview of the clinical trial design, which uses a double-blind multi-dose strategy across five separate test days to examine dose-dependent effects of D1R/D5R partial agonism on working memory neural circuits.

Article Snippet: Non-human primate studies conducted by Pfizer describe dose-related improvements in sWM , and with chronic intermittent administration, even lower doses of D1R/D5R agonists that were without initial benefit also exhibited procognitive effects ( ).

Techniques: Biomarker Assay

Journal: Advanced Science

Article Title: Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives

doi: 10.1002/advs.202413786

Figure Lengend Snippet: Psychedelic research in a rodent model.

Article Snippet: ERK, D1R, and c‐fos , , 50 mg kg −1 , IP (Once a day for 7 d) , Male Sprague Dawley rats , Ketamine abuse model was established administration of ketamine IP injection. , Ketamine abusing enhanced the anxious behavior and disrupted NAc , [ ] .

Techniques: Activation Assay, Gene Expression, Activity Assay, Conditioned Place Preference, Injection, Transmission Assay, Mutagenesis, Mouse Assay, Microinjection, Saline

Journal: Advanced Science

Article Title: Psychedelic Drugs in Mental Disorders: Current Clinical Scope and Deep Learning‐Based Advanced Perspectives

doi: 10.1002/advs.202413786

Figure Lengend Snippet: Overview of psychedelic drugs and receptors in mental disorders. Psychedelic drugs, including psilocybin, MDMA, LSD, ketamine, ibogaine, and ayahuasca (DMT as an active component in ayahuasca brew), have renewed interest in treating psychiatric disorders. Emerging psychedelics are harnessed to restore symptoms against poor response rates to traditional medications, such as major depressive disorder (MDD), posttraumatic stress disorder (PTSD), obsessive‒compulsive disorder, autism spectrum disorder (ASD), and substance use disorders (SUD) (e.g., alcohol and opioid). Some psychedelics interact collectively with diverse types or subtypes of receptors, and vice versa, owing to the structural similarities of cognate neurotransmitters. The psychedelics confer potentiation through their engaged receptors in a wide spectrum of improved outcomes. The interactive mechanism between psychedelics and receptors in response to mental disorders is still unclear and requires an explanation of which drugs are best suited to initiate a cascade. 5‐HTR: 5‐hydroxytryptamine receptor; AMPAR: α‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid receptor; D1R: dopamine D1 receptor; TrkB: tropomyosin receptor kinase B; MDMA: N‐methyl‐3,4‐methylenedioxyamphetamine; LSD: lysergic acid diethylamide; NMDAR: N‐methyl‐D‐aspartate receptor. The figure was created with BioRender.com .

Article Snippet: ERK, D1R, and c‐fos , , 50 mg kg −1 , IP (Once a day for 7 d) , Male Sprague Dawley rats , Ketamine abuse model was established administration of ketamine IP injection. , Ketamine abusing enhanced the anxious behavior and disrupted NAc , [ ] .

Techniques: Medications